Resource Roadmap To Screening Success

The Resource Roadmap to Screening Success focuses on accelerating the development of cell-based therapies, including CAR-T and T-cell therapies, through innovative tools and workflows. Traditional workflows in cell-based therapy are expensive, time-consuming, and limited in exploration capabilities. Sartorius offers the T-Cell Exploration and Characterization Solution, which integrates high-throughput systems like the Ambr® 15 and Ambr® 250 bioreactors. These tools are supported by MODDE® Design of Experiments (DOE) software to identify and optimize critical process parameters (CPPs) and quality attributes (CQAs). Key innovations include automated bioreactor systems and serum-free media, which enhance cell yield, viability, and reproducibility while minimizing the risks associated with human serum.

Advanced analytics tools such as the iQue® flow cytometer and Incucyte® SX5 live-cell analyzer allow scientists to monitor key biomarkers and cell characteristics in real-time. Sartorius' integrated solution reduces the time and cost of process optimization by up to 50% compared to traditional methods, paving the way for more efficient scale-up and commercialization of therapies. By improving process knowledge early on, these technologies help lower production risks and ensure the consistent quality of therapeutic products. The roadmap provides detailed insights into optimizing CAR-T processes, ensuring seamless transfer from small-scale experiments to large-scale manufacturing, thus making cell therapies more accessible to patients.